Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 56
Filtrar
Mais filtros

País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Int J Mol Sci ; 24(14)2023 Jul 22.
Artigo em Inglês | MEDLINE | ID: mdl-37511561

RESUMO

There has been increasing interest in the study of new pathogenic mechanisms in endometriosis (END), including the coagulation/fibrinolysis system and its link with inflammation and tissue remodeling. It has been suggested that END patients, especially with deep-infiltrating (DE) forms, could present a hypercoagulable state revealing higher levels of proinflammatory and procoagulant markers, such as total circulating microparticles (cMPs) and cMP-TF (tissue factor), released by cells in response to damage, activation, or apoptosis. However, no previous study has assessed the effect of END hormonal treatments on cMP and cMP-TF levels. Therefore, the aim of this study was to evaluate the impact of these treatments on cMP and cMP-TF levels in DE patients. Three groups were compared: DE patients receiving a continuous combined oral contraceptive regimen (CCOCR) (n = 41), DE patients without CCOCR (n = 45), and a control group (n = 43). cMP and cMP-TF levels were evaluated in platelet-free plasma. A significant decrease in the total cMP levels was found in the DE group with CCOCR versus the group without CCOCR, reflecting a higher chronic inflammatory status in DE patients that decreased with the treatment. cMP-TF levels were higher in DE patients receiving CCOCR versus those not receiving CCOCR, suggesting that treatments containing estrogens play a predominant role in suppressing the inhibitory pathway of TF.


Assuntos
Micropartículas Derivadas de Células , Endometriose , Feminino , Humanos , Endometriose/patologia , Etinilestradiol , Norpregnenos/metabolismo , Coagulação Sanguínea , Tromboplastina/metabolismo , Inflamação/metabolismo , Micropartículas Derivadas de Células/metabolismo
2.
Thromb J ; 20(1): 75, 2022 Dec 13.
Artigo em Inglês | MEDLINE | ID: mdl-36510196

RESUMO

BACKGROUND: Thromboelastometry is considered the best method to assesses hemostasis in liver disease. Diagnostic performance could be improved by adding protein C activators such as thrombomodulin or Protac®. We assessed changes in ROTEM parameters after the addition of Protac® in patients with acute-on-chronic liver failure (ACLF), acute decompensation (AD), and healthy individuals (HI) to define different hemostasis patterns, considering standard and velocity ROTEM parameters, and assess whether Protac® can improve the definition of the pattern. METHODS: Pre-test, we investigated whether diluted EXTEM reagent improved the effect of Protac® on the clotting time (CT)-ratio with and without Protac®. Ten ACLF and 20 AD patients and 21 HI were included in the main study. RESULTS: Standard EXTEM was used in the main study. INTEM CFT, INTEM A5 (inverse), and INTEM TPI (inverse) were the parameters that best differentiated liver disease from HI (ROC AUC, 0.921, 0.906, and 0.928, respectively; all P-values < 0.001). Combining INTEM CFT with EXTEM LI60-ratio only slightly improved the diagnostic performance (ROC AUC, 0.948; P < 0.001). EXTEM LI60 and INTEM maxV-t were the parameters that best differentiated between ACLF and AD patients (ROC AUC, 0.743, P = 0.033; and 0.723, P = 0.050; respectively). Combining EXTEM LI60 + INTEM maxV-t moderately improved the diagnostic performance (ROC AUC, 0.81, P < 0.001). CONCLUSIONS: ROTEM velocity, fibrinolysis parameters and the indices calculated improve the diagnosis in combination with standard parameters (e.g., CFT and A5). Ratios calculated with and without Protac® (e.g., EXTEM LI60-ratio) only slightly increased the diagnostic performance in discriminating hemostasis patterns.

3.
Transfusion ; 61(10): 3008-3016, 2021 10.
Artigo em Inglês | MEDLINE | ID: mdl-34358342

RESUMO

BACKGROUND: Antivitamin K agent (AVK) reversal in patients with cirrhosis awaiting liver transplantation (LT) is not defined in guidelines. We investigated the effect of reversion with prothrombin complex concentrate (PCC) on intraoperative transfusion, bleeding, and safety in LT patients on AVK. STUDY DESIGN AND METHODS: In 511 patients undergoing LT, we identified 25 patients treated with AVK (AVK group) and 13 patients with incidental portal vein thrombosis (PVT) without AVK (incidental PVT group). Fifty patients who underwent LT without PVT or AVK matched by age, model for end stage of liver disease (MELD), body mass index (BMI), and cirrhosis etiology were selected as the control group. RESULTS: There were no significant differences between the three groups in intraoperative blood loss, transfusion, and postoperative bleeding. In the AVK group, there were no differences between patients who received PCC and those who did not in intraoperative blood loss, red blood cells, fibrinogen, and platelet transfusion, or postoperative bleeding. PCC use had no effect on RBC transfusion in patients who had international normalized ratio or clotting time above versus below median values of the two parameters at baseline (2.3 and 103 s, respectively). No thrombotic events were detected in patients who received PCC. DISCUSSION: These data suggest that systematic administration of PCC to revert AVK prior to LT should be reconsidered.


Assuntos
4-Hidroxicumarinas/uso terapêutico , Fatores de Coagulação Sanguínea/uso terapêutico , Indenos/uso terapêutico , Cirrose Hepática/terapia , Transplante de Fígado , Vitamina K/antagonistas & inibidores , Transfusão de Sangue , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Vitamina K/uso terapêutico
4.
J Thromb Thrombolysis ; 52(1): 30-41, 2021 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-33011897

RESUMO

Microparticles (MPs) have been associated with inflammatory and thrombotic disease. High levels of MPs have been identified in patients with systemic lupus erythematosus (SLE) and associated with cardiovascular disease. We analyzed the procoagulant activity of MPs and its correlation with arteriosclerosis and arterial thrombosis in SLE patients. Eighty-seven patients with SLE were included: 22 (25.3%) with associated antiphospholipid syndrome (APS), 32 (36.8%) without antiphospholipid antibodies (aPL) and 33 (37.9%) with aPL but without APS. Subclinical arteriosclerosis, defined as the presence and number of plaques, was evaluated by ultrasonography of carotid arteries. Thrombotic events were confirmed by objective methods. The procoagulant activity of MPs was determined by a functional assay with annexin V. Subclinical arteriosclerosis was found in 19 (21.8%) patients. Thirteen episodes of arterial thrombosis and eight of venous thrombosis were recorded. The procoagulant activity of MPs was greater in patients with arterial thrombosis (17.28 ± 8.29 nM vs 12.96 ± 7.90 nM, p < 0.05). In patients without arterial thrombosis, greater procoagulant activity of MPs was identified in patients with multiple (≥ 2) carotid plaques (17.26 ± 10.63 nM vs 12.78 ± 7.15 nM, p = 0.04). In the multivariate analysis, the procoagulant activity of MPs was independently associated with multiple (≥ 2) carotid plaques and arterial thrombosis [OR = 1.094 (95%CI 1.010-1.185), p = 0.027 and OR = 1.101 (95%CI 1.025-1.182), p = 0.008; respectively]. In conclusion, the procoagulant activity of MPs is associated with arteriosclerosis burden and arterial thrombosis in patients with SLE.


Assuntos
Síndrome Antifosfolipídica , Arteriosclerose , Lúpus Eritematoso Sistêmico , Trombose , Anticorpos Antifosfolipídeos , Síndrome Antifosfolipídica/complicações , Humanos , Lúpus Eritematoso Sistêmico/complicações , Trombose/etiologia
5.
Lupus ; 29(9): 1050-1059, 2020 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-32536318

RESUMO

OBJECTIVE: The objective of this paper is to assess the prevalence of the main clinical manifestations and laboratory features at disease onset and during the ensuing 10 years of a large cohort of patients with antiphospholipid syndrome (APS) from a single center. METHODS: The study included all consecutive APS patients followed longitudinally in our center from 2003 to 2013. Descriptive statistics for demographics, clinical and laboratory features and mortality were performed. RESULTS: A total of 160 patients were included. Most of them, 128 (78.8%), were women and the mean (SD) age at diagnosis was 39.1 (14.0) years. The majority of them, 104 (65.0%), had primary APS, 36 (22.5%) had APS associated with systemic lupus erythematous, and 20 (12.5%) had APS associated with other autoimmune disease. During the study period, thrombotic events occurred in 27 (16.9%) patients, the most common being strokes, nonbacterial thrombotic endocarditis and deep venous thrombosis. Regarding obstetric morbidity, 18 women (14.3%) became pregnant and 90% of pregnancies succeeded in having live births. The most common obstetric complication was early pregnancy loss (15% of pregnancies). Prematurity (11.1% of live births) and intrauterine growth restriction (5.6% of live births) were the most frequent fetal morbidities. Ten (6.3%) patients died and the most frequent causes of death were severe thrombosis, hemorrhage, and cancer. Three (0.9%) cases of catastrophic APS occurred. The survival probability at 10 years was 93.8%. CONCLUSIONS: Patients with APS develop significant morbidity and mortality despite current treatment. It is imperative to identify prognostic factors and therapeutic measures to prevent these complications.


Assuntos
Aborto Espontâneo/epidemiologia , Síndrome Antifosfolipídica/mortalidade , Lúpus Eritematoso Sistêmico/mortalidade , Trombose/mortalidade , Adulto , Síndrome Antifosfolipídica/complicações , Causas de Morte , Feminino , Retardo do Crescimento Fetal/epidemiologia , Humanos , Estudos Longitudinais , Lúpus Eritematoso Sistêmico/complicações , Masculino , Pessoa de Meia-Idade , Gravidez , Resultado da Gravidez/epidemiologia , Espanha , Acidente Vascular Cerebral/etiologia , Acidente Vascular Cerebral/mortalidade , Trombose/etiologia , Trombose Venosa/etiologia , Trombose Venosa/mortalidade
6.
J Minim Invasive Gynecol ; 26(3): 450-455, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-29803597

RESUMO

STUDY OBJECTIVE: To evaluate serial generation of microparticles (MPs) after laparoscopic stripping or CO2 laser vaporization in the surgical treatment of patients with ovarian endometrioma (OE). DESIGN: A prospective, randomized, blinded, pilot study (Canadian Task Force classification I). SETTING: Tertiary care university hospital from December 2014 to July 2016. PATIENTS: Thirty women with unilateral OE undergoing laparoscopic surgery. INTERVENTION: Patients were randomly selected to undergo either CO2 laser vaporization (L group) or laparoscopic stripping (S group) of OE. MEASUREMENTS AND MAIN RESULTS: Blood samples were collected before surgery and at 2 hours, 24 hours, 1 month, and 3 months after surgery. An MP generation curve after OE surgery was created. MP generation was greater in the S group than in the L group at all time points evaluated. The MP generation curve showed a significantly higher area under the curve after excisional surgery (p <.05). CONCLUSION: The higher MP levels in the S group suggest an increased inflammation and procoagulant response after this procedure.


Assuntos
Endometriose/cirurgia , Doenças Ovarianas/cirurgia , Adulto , Endometriose/sangue , Feminino , Humanos , Laparoscopia/métodos , Terapia a Laser/métodos , Lasers de Gás , Doenças Ovarianas/sangue , Projetos Piloto , Estudos Prospectivos
7.
Reprod Biomed Online ; 33(2): 168-73, 2016 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-27236712

RESUMO

Cell-derived microparticles (cMPs) are small membrane vesicles that are released from many different cell types in response to cellular activation or apoptosis. Elevated cMP counts have been found in almost all thrombotic diseases and pregnancy wastage, such as recurrent spontaneous abortion and in a number of conditions associated with inflammation, cellular activation and angiogenesis. cMP count was investigated in patients experiencing unexplained recurrent implantation failure (RIF). The study group was composed of 30 women diagnosed with RIF (RIF group). The first control group (IVF group) (n = 30) comprised patients undergoing a first successful IVF cycle. The second control group (FER group) included 30 healthy women who had at least one child born at term and no history of infertility or obstetric complications. cMP count was significantly higher in the RIF group compared with the IVF and FER groups (P < 0.05 and P < 0.01, respectively) (RIF group: 15.8 ± 6.2 nM phosphatidylserine equivalent [PS eq]; IVF group: 10.9 ± 5.3 nM PS eq; FER group: 9.6 ± 4.0 nM PS eq). No statistical difference was found in cMP count between the IVF and FER groups. Increased cMP count is, therefore, associated with RIF after IVF and embryo transfer.


Assuntos
Micropartículas Derivadas de Células , Implantação do Embrião , Fertilização in vitro/métodos , Aborto Habitual , Aborto Espontâneo/diagnóstico , Adulto , Apoptose , Estudos de Casos e Controles , Transferência Embrionária , Feminino , Humanos , Infertilidade Feminina/terapia , Inflamação , Obstetrícia , Fosfatidilserinas/química , Gravidez , Estudos Prospectivos , Recidiva , Estudos Retrospectivos , Trombose
8.
Circ J ; 79(2): 331-8, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25482382

RESUMO

BACKGROUND: Despite the good safety of rivaroxaban, there is limited information on strategies for urgent reversal of its antihemostatic effects. METHODS AND RESULTS: Alterations of hemostasis induced by rivaroxaban (230 ng/ml) were assessed by using several tests applied to steady and circulating human blood. Effects on thrombin generation (TG) and thromboelastometry (TEM) parameters were measured. Modifications in platelet adhesive, aggregating and procoagulant activities were evaluated in studies with circulating blood. The potential reversal of prothrombin complex concentrates (PCCs; 50 IU/kg), activated PCCs (aPCCs; 75 IU/kg), or recombinant factor VIIa (rFVIIa; 270 µg/kg) was evaluated. Impairment of TG parameters induced by rivaroxaban were corrected by the different concentrates (aPCC≥PCC>rFVIIa). Prolonged clotting times and reduced clot firmness caused by rivaroxaban on TEM tests were improved by different concentrates (rFVIIa≥aPCC>PCC). Rivaroxaban significantly reduced platelets and fibrin interactions with damaged vascular surfaces in perfusion studies. While alterations of platelet interactions were favourably counteracted by rFVIIa or aPCCs, reductions in fibrin formation were only partially restored by the different factor concentrates (rFVIIa>aPCC≥PCC). CONCLUSIONS: Rivaroxaban-induced alterations on coagulation parameters measured through assays performed under static conditions were easily reversed by the different concentrates. Studies under flow conditions revealed that these concentrates normalized the action of rivaroxaban on platelets, and significantly improved fibrin formation; although in the later case, levels were not restored to the pre-treatment value.


Assuntos
Fatores de Coagulação Sanguínea/farmacologia , Fator VIII/farmacologia , Fator VIIIa/farmacologia , Hemostasia/efeitos dos fármacos , Rivaroxabana/farmacologia , Humanos
9.
Clin Exp Rheumatol ; 32(4 Suppl 84): S67-71, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25068444

RESUMO

OBJECTIVES: To analyse the relationship between an automated thrombin generation test, the endogenous thrombin potential (ETP), and other hypercoagulability markers, with vascular involvement in patients with Behçet's disease (BD). Patients and methods. We analysed 56 BD patients (30 men; mean age, 34.4 ± 14.3 years) without any known thrombophilic factor, of which 17 had previously suffered from thrombosis (deep venous thrombosis in 14 and ischaemic stroke in 3), and 56 controls matched for age and sex. Additionally, we also evaluated 20 plasma samples with an international normalised ratio (INR) between 1.5 and 5.0 obtained from patients with atrial fibrillation but without a history of embolic events that were under treatment with acenocumarol. Thrombin generation was measured as ETP with a chromogenic assay in an automated analyser. Factor VIII, von Willebrand factor antigen, prothrombin fragment 1.2, D-dimer and plasmin-antiplasmin complexes were also measured. RESULTS: BD patients showed higher ETP values than controls (471.3± 49.3 vs. 427.5± 31.3 mA; p<0.001). Additionally, BD patients with a history of thrombosis had higher ETP values than patients without thrombosis (496.6± 36.5 vs. 460.7± 50.5 mA; p<0.01). Factor VIII and von Willebrand factor antigen were also elevated in BD patients, but only von Willebrand factor antigen showed statistically significant differences between BD patients with and without thrombosis. Acenocumarol treatment reduced thrombin generation in BD patients in parallel to INR levels, reaching values similar to those of patients with atrial fibrillation and similar INR. CONCLUSIONS: BD is associated with thrombosis, and increased thrombin generation (measured as ETP) is a promising marker of hypercoagulability.


Assuntos
Anticoagulantes/uso terapêutico , Síndrome de Behçet/sangue , Trombina/metabolismo , Trombofilia/sangue , Trombofilia/diagnóstico , Trombose Venosa/sangue , Acenocumarol/uso terapêutico , Adulto , Biomarcadores/sangue , Testes de Coagulação Sanguínea , Isquemia Encefálica/sangue , Isquemia Encefálica/tratamento farmacológico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Protrombina/metabolismo , Trombose Venosa/tratamento farmacológico , Adulto Jovem
10.
Clin Exp Rheumatol ; 31(6): 926-32, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24093662

RESUMO

OBJECTIVES: The current case-control study was aimed to determine the prevalence and the clinical significance of inherited thrombophilia - factor V Leiden and G20210A prothrombin polymorphisms - in patients with antiphospholipid syndrome (APS). METHODS: 100 patients with APS (77 with primary APS and 23 with systemic lupus erythematosus [SLE]-APS), and 100 patients with first lower extremity deep venous thrombosis (DVT), and 200 healthy individuals as a control groups were analysed. Patients and control group were tested for factor V Leiden and prothrombin G20210A gene polymorphism. RESULTS: Factor V Leiden variant was found in 1% of APS patients, in 3% of healthy individuals (p=0.49), and 16% of patients with first DVT (p<0.0005). Prothrombin gene polymorphism was found in 6% of APS patients and in 2.5% of healthy subjects (p=0.21), and 13% of patients with DVT (p=0.14). In primary APS patients, factor V Leiden was present in 1.3% (1/77) and prothrombin gene polymorphism in 6.5% (5/77). No patient with SLE-APS had factor V Leiden and prothrombin gene variant was present in only one patient (4.3%). Patients with prothrombin polymorphism had higher prevalence of venous thrombosis, with no statistical significance (80% vs. 47.9%, p=0.35). There were no differences in the prevalence of recurrent thrombosis before or after APS diagnosis in patients with or without prothrombin gene polymorphism. CONCLUSIONS: Factor V Leiden and G20210A prothrombin variant seem to play no role in either the development of APS or in the type of involved vessel, with no increased risk of re-thrombosis during follow-up.


Assuntos
Resistência à Proteína C Ativada/epidemiologia , Resistência à Proteína C Ativada/genética , Síndrome Antifosfolipídica/epidemiologia , Fator V/genética , Protrombina/genética , Resistência à Proteína C Ativada/sangue , Resistência à Proteína C Ativada/diagnóstico , Adulto , Síndrome Antifosfolipídica/sangue , Síndrome Antifosfolipídica/diagnóstico , Estudos de Casos e Controles , Distribuição de Qui-Quadrado , Feminino , Predisposição Genética para Doença , Humanos , Masculino , Pessoa de Meia-Idade , Fenótipo , Polimorfismo Genético , Prevalência , Prognóstico , Recidiva , Medição de Risco , Fatores de Risco , Espanha/epidemiologia , Trombose Venosa/epidemiologia , Adulto Jovem
11.
Int J Colorectal Dis ; 28(9): 1281-6, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23588875

RESUMO

PURPOSE: In inflammatory bowel diseases (IBD), risk of thrombosis and production of antibodies are increased. In autoimmune and inflammatory disorders, a role of anti-prothrombin (aPT) antibodies in developing thrombosis has been hypothesised. The aim of the study is to evaluate the prevalence of aPT antibodies in IBD patients, with and without thrombosis. METHODS: Thirty-three IBD patients with thrombosis, 33 IBD patients without thrombosis matched for sex, age, diagnosis and disease activity and 66 sex- and age-matched healthy controls were enrolled. Thrombosis was considered recent when blood sample was obtained within 3 months from the event. RESULTS: Prevalence of aPT antibodies in thrombotic IBD patients (3/33, 9.1 %), non-thrombotic IBD patients (4/33, 12.1 %) and in healthy subjects (3/66, 4.5 %) did not result significantly different (p = 0.377). The prevalence of aPT antibodies was more frequent in ulcerative colitis (6/32, 18.7 %) than in Crohn's disease (1/34, 2.9 %) and healthy controls (p = 0.022). Among thrombotic IBD patients, the prevalence of aPT antibodies was higher in those with recent (2/9, 22.2 %) than in those with previous thrombosis (1/24, 4.2 %) (p = 0.103). All thrombotic IBD patients with aPT antibodies were affected by ulcerative colitis with previous history of deep venous thrombosis. CONCLUSIONS: aPT antibodies do not appear to play a relevant role in thrombosis complicating IBD course. A possible association in ulcerative colitis patients with DVT could not be excluded.


Assuntos
Anticorpos/sangue , Doenças Inflamatórias Intestinais/sangue , Doenças Inflamatórias Intestinais/complicações , Protrombina/imunologia , Trombose/sangue , Trombose/etiologia , Estudos de Casos e Controles , Demografia , Feminino , Humanos , Doenças Inflamatórias Intestinais/diagnóstico , Doenças Inflamatórias Intestinais/imunologia , Masculino , Pessoa de Meia-Idade , Trombose/diagnóstico , Trombose/imunologia
12.
Clin Gastroenterol Hepatol ; 10(1): 72-8, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-21946303

RESUMO

BACKGROUND & AIMS: Although they have normal liver histology and function, patients with chronic noncirrhotic nontumoral portal vein thrombosis (NC-PVT) frequently have abnormal results from coagulation tests. We investigated the significance of these results. METHODS: We analyzed blood samples collected from 50 stable patients with NC-PVT secondary to a thrombophilic disorder (32%) or local factor (32%), or that was idiopathic (36%). We measured endogenous thrombin potential (ETP) with and without thrombomodulin, prothrombin time, activated partial thromboplastin time, coagulation factors (I, II, V, VII, VIII, IX, X, XI, and XII), antithrombin, proteins C and S, von Willebrand factor (vWF) antigen, vWF ristocetin cofactor, a disintegrin and metalloprotease with thrombospondin type 1 motifs 13 antigen, D-dimer, plasmin-antiplasmin complex, prothrombin fragment F1+2, activated factor VII, and clot lysis time. Samples from 50 age- and sex-matched healthy individuals were evaluated as controls. RESULTS: Compared with controls, patients with NC-PVT had significant increases in prothrombin time and activated partial thromboplastin time; they had significant reductions in levels of procoagulant factors II, V, VII, IX, X, XI, and XII, and the anticoagulants antithrombin, protein C, and protein S. The patients had increased levels of factor VIII and vWF antigen. Irrespective of etiology, patients with NC-PVT had a significant increase in ETP with thrombomodulin and higher levels of factor VIIa, prothrombin fragment F1+2, D-dimer, and plasmin-antiplasmin complex than controls, indicating in vivo activation of coagulation and fibrinolysis. CONCLUSIONS: Patients with NC-PVT have hypercoagulability that is independent of the underlying etiology, based on in vitro analyses of thrombin-generation capacity and increased levels of biomarkers in blood samples. Further studies are required to determine if activation of hemostasis increases the risk for thrombotic events.


Assuntos
Veia Porta/patologia , Trombofilia/diagnóstico , Trombose/complicações , Adolescente , Adulto , Idoso , Fatores de Coagulação Sanguínea/análise , Doença Crônica , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Tempo de Tromboplastina Parcial , Tempo de Protrombina , Trombose/patologia , Adulto Jovem
13.
Ann Rheum Dis ; 71(1): 61-6, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-21900285

RESUMO

OBJECTIVE: To investigate whether patients having antiphospholipid syndrome (APS) as the only aetiological factor for recurrent spontaneous abortion (RSA) are at increased risk of thrombosis later in life. METHODS: A case-control study at a tertiary university referral centre. The study group consisted of 57 primary APS and RSA women (APS-RSA group). Control groups included: 86 patients with RSA of unknown aetiology (uRSA group), 42 patients with RSA and thrombophilic genetic defects as the only aetiologic factor for RSA (tRSA group) and 30 antiphospholipid antibody (aPL) positive but otherwise healthy women (aPL group). The main measurement was the thrombosis rate after long-term follow-up. RESULTS: APS-RSA patients had a significantly higher 12-year cumulative thrombotic incidence rate compared with the three comparator groups (19.3% vs 4.8%, 0.0% and 0.0%, respectively (log rank), p<0.001). Patients in the APS-RSA group had 25.6 thrombotic events per 1000 patient-years (95% CI 12.8 to 45.9). The OR of thrombosis in relation to the presence (APS-RSA group) or absence (uRSA and tRSA groups) of aPL in patients with RSA was 15.06 (95% CI 3.2 to 70.5). CONCLUSIONS: Our data indicate that a history of RSA associated with aPL is a risk factor for subsequent thrombosis in the long term.


Assuntos
Aborto Habitual/etiologia , Síndrome Antifosfolipídica/complicações , Tromboembolia/etiologia , Adulto , Métodos Epidemiológicos , Feminino , Humanos , Pessoa de Meia-Idade , Gravidez , Prognóstico , Risco , Adulto Jovem
14.
Hum Reprod ; 26(3): 510-6, 2011 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-21216787

RESUMO

BACKGROUND: Recurrent implantation failure (RIF) following embryo transfer (ET) is a major continuing problem in IVF. Women with haemostatic defects may be at increased risk of miscarriage and preclinical pregnancy loss. The fibrinolytic system is considered, at present, the key to new thrombotic pathogenic mechanisms. Patients with unexplained recurrent miscarriage have an impairment of fibrinolysis, as demonstrated by prolonged clot lysis time (CLT) in association with increased plasma levels of thrombin-activatable fibrinolysis inhibitor (TAFI). In this study, we investigated fibrinolytic potential in patients with RIF. METHODS: Three groups of patients were studied: 30 women with RIF (RIF group), 60 patients undergoing a first successful IVF-ET cycle (IVF group) and 60 healthy fertile women (FER group). Plasma CLT was measured using a global fibrinolysis assay. TAFI antigen plasma levels and polymorphisms in the TAFI gene (+505A/G and +1542C/G) were analysed using enzyme-linked immunosorbent assay and allele-specific PCR, respectively. RESULTS: CLT was significantly longer (P < 0.0001 and P < 0.0009, respectively) and TAFI antigen levels were significantly higher (both P < 0.0001) in the RIF versus the IVF and FER groups. A direct relationship between CLT and TAFI antigen levels (r = 0.40; P = 0.001) was detected in the whole study population. There were no differences in distribution of TAFI polymorphisms between groups. CONCLUSIONS: Patients with RIF have reduced plasma fibrinolytic potential, as shown by a prolonged CLT, and this may be explained, at least in part, by increased TAFI antigen levels.


Assuntos
Transferência Embrionária , Fertilização in vitro , Fibrinólise , Infertilidade/sangue , Infertilidade/terapia , Trombose/complicações , Alelos , Carboxipeptidase B2/sangue , Carboxipeptidase B2/genética , Feminino , Testes Hematológicos , Humanos , Infertilidade/complicações , Infertilidade/genética , Infertilidade Feminina/sangue , Infertilidade Feminina/complicações , Infertilidade Feminina/genética , Infertilidade Feminina/terapia , Polimorfismo de Nucleotídeo Único , Estudos Retrospectivos , Fatores de Risco , Espanha , Falha de Tratamento
15.
Blood Adv ; 5(19): 3821-3829, 2021 10 12.
Artigo em Inglês | MEDLINE | ID: mdl-34521101

RESUMO

The Spanish Acquired Hemophilia A (AHA) Registry is intended to update the status of AHA in Spain. One hundred and fifty-four patients were included and retrospectively followed for a median of 12 months. Patients were predominantly male (56.3%), with median age at diagnosis of 74 years. AHA was more frequently idiopathic (44.1%) and autoimmune disorder-associated (31.7%). Thirty-four percent of patients were on antithrombotic therapy at diagnosis. Hemostatic treatment was used in 70% of patients. Recombinant activated factor VII was more frequently infused (60.3% vs 20.6% activated prothrombin complex concentrate). Only 1 patient did not achieve control of hemorrhage. Complete remission (CR) was achieved by 84.2% of cases after immunosuppressive therapy. Steroids alone were less efficient than the other strategies (68.2% vs 87.2%, P = .049), whereas no differences existed among these (steroids/cyclophosphamide, 88.5%, vs steroids/calcineurin inhibitors, 81.2%, vs rituximab-based regimens, 87.5%). Female sex and high inhibitor levels influenced CR negatively. Thirty-six deaths (23.8%) were reported. Main causes of death were infection (15 patients, 9.9%) and hemorrhage (5 patients, 3.3%). All hemorrhage-related and half the infection-related deaths occurred within 2 months of diagnosis. Prior antithrombotic therapy was inversely associated with survival, irrespective of age. Median age of nonsurvivors was significantly higher (79 vs 73 years in survivors). Patients dying of infection were older than the other nonsurvivors (85 vs 78 years). In summary, fatal infection in the first months is common in our series. Antithrombotic therapy is associated with mortality. Particular care should be taken to avoid misdiagnosis.


Assuntos
Hemofilia A , Idoso , Autoanticorpos , Fator VIII , Feminino , Hemofilia A/diagnóstico , Hemofilia A/tratamento farmacológico , Hemofilia A/epidemiologia , Humanos , Masculino , Sistema de Registros , Estudos Retrospectivos
16.
Am J Obstet Gynecol ; 201(1): 87.e1-6, 2009 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19427615

RESUMO

OBJECTIVE: The purpose of this study was to analyze the in vitro activation of the contact complex with the use of human umbilical vein endothelial cells (HUVEC) in culture and monoclonal anticardiolipin antibodies (MaCL). STUDY DESIGN: Cultured HUVECs were incubated with pooled plasma from third-trimester pregnant women with the addition (20 mg/mL) of MaCL with anti-beta-2 glycoprotein I activity that was obtained from patients with antiphospholipid syndrome (APS), MaCL from an individual without APS, or from a control patient with immunoglobulin M without aCL activity. Supernatants were evaluated. Activated factors XII and VII, prothrombin-fragment 1 + 2, urokinase-type plasminogen activator (UPA), and differentiating 2 chain UPA were determined. RESULTS: In the cultured HUVEC supernatants, the addition of MaCL increased activated factor VII and prothrombin-fragment 1 + 2, did not modify UPA, and decreased activated factor XII and differentiating 2 chain UPA, in comparison with samples with control immunoglobulin M added. The MaCL without APS activity did not change any parameter that was evaluated. CONCLUSION: MaCL with anti-beta-2 activity that was obtained from patients with APS may interfere in the activation of the contact complex during pregnancy.


Assuntos
Anticorpos Antifosfolipídeos/imunologia , Fator XIIa/imunologia , Fibrinólise/imunologia , Gravidez/imunologia , Adulto , Idoso , Síndrome Antifosfolipídica/imunologia , Células Cultivadas , Endotélio Vascular , Feminino , Humanos , Técnicas In Vitro , Masculino , Fragmentos de Peptídeos/sangue , Fragmentos de Peptídeos/imunologia , Gravidez/fisiologia , Complicações na Gravidez/fisiopatologia , Terceiro Trimestre da Gravidez , Protrombina/imunologia , Trombose/fisiopatologia , Veias Umbilicais/citologia
17.
Reprod Sci ; 26(1): 70-76, 2019 01.
Artigo em Inglês | MEDLINE | ID: mdl-29448896

RESUMO

Neutrophil extracellular traps (NETs) have been described to be related to the pathogenesis of inflammatory and autoimmune conditions. Endometriosis is currently considered a chronic inflammatory condition. Therefore, we performed a preliminary case-control study to compare the circulating plasma NET levels in patients with surgically confirmed endometriosis (E group, n = 82) and those of patients without surgical findings of endometriosis (C group, n = 35). Venous blood samples were obtained at the time of surgery. Circulating plasma NET levels were assessed as histone-DNA complexes (ie, nucleosomes) by a quantitative sandwich enzyme-linked immunosorbent assay. The results were expressed in arbitrary units. Circulating plasma NET levels were significantly higher in the E group compared with the C group (median [25th; 75th percentiles]): E group: 0.734 [0.484; 1.363]; C group: 0.541 [0.411; 0.653]; P = .005). The subanalysis of E group patients with deep infiltrating endometriosis (DIE group) or without DIE (non-DIE group) showed that plasma NET levels were higher in the DIE group ( P = .02). No differences were observed in NET levels among patients with and without severe pelvic pain or in patients with and without infertility, regardless of the presence of endometriotic lesions. Therefore, our study shows significantly higher NET levels in patients with endometriosis, which seem to be attributed to increased levels in the subgroup of patients with DIE, suggesting that the presence of elevated circulating plasma NET levels may reflect an inflammatory status in this gynecological condition. Further research is warranted to confirm our findings and to assess the exact role of NETs in the pathophysiological mechanisms of endometriosis.


Assuntos
Endometriose/sangue , Armadilhas Extracelulares/metabolismo , Inflamação/complicações , Adulto , Estudos de Casos e Controles , Endometriose/complicações , Feminino , Humanos , Inflamação/sangue , Nucleossomos/metabolismo
18.
Methods Mol Biol ; 1955: 275-286, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30868535

RESUMO

The most severe clinical symptomatology of Chagas disease affects ~30% of those chronically infected with the Trypanosoma cruzi parasite. The pathogenic mechanisms that lead to life-threatening heart and gut tissue disruptions occur "silently" for a longtime in a majority of cases. As a result, despite there are several serological and molecular methods available to diagnose the infection in its acute and chronic stages, diagnosis is often achieved only after the onset of clinical symptoms in the chronic phase of the disease. Furthermore, although there are two drugs to treat it, the assessment of their performance is impractical with current parasite-derived diagnostics, and therapeutic efficacy cannot be acknowledged in a timely manner.In this chapter we present two procedures to measure host-derived molecules as surrogates of therapeutic response against chronic T. cruzi infection. Their outputs relate to the generation and activity of thrombin, a major component of the blood coagulation cascade. This is due to the fact that a hypercoagulability state has been described to occur in chronic Chagas disease patients and revert after treatment with benznidazole.


Assuntos
Doença de Chagas/sangue , Trombina/análise , Trombofilia/sangue , Biomarcadores/sangue , Doença de Chagas/complicações , Doença de Chagas/diagnóstico , Doença de Chagas/tratamento farmacológico , Doença Crônica , Ensaio de Imunoadsorção Enzimática/métodos , Humanos , Nitroimidazóis/uso terapêutico , Prognóstico , Trombofilia/complicações , Trombofilia/diagnóstico , Trombofilia/tratamento farmacológico , Tripanossomicidas/uso terapêutico , Trypanosoma cruzi/efeitos dos fármacos
19.
Thromb Haemost ; 119(9): 1409-1418, 2019 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-31254973

RESUMO

Presently, no data on the molecular basis of hereditary protein C (PC) deficiency in Spain is available. We analyzed the PC gene (PROC) in 109 patients with symptomatic PC deficiency and in 342 relatives by sequencing the 9 PROC exons and their flanking intron regions. In 93 probands, we found 58 different mutations (26 novel). Thirty-seven consisted of a nucleotide change, mainly missense mutations, 1 was a 6-nucleotide insertion causing the duplication of 2 amino acids, and 4 were deletions of 1, 3, 4, and 16 nucleotides. Nine mutations caused type II deficiencies, with the presence of normal antigen levels but reduced anticoagulant activity. Using a PC level of 70% as lowest normal limit, we found no mutations in 16 probands and 25 relatives with PC levels ≤ 70%. On the contrary, 4 probands and 12 relatives with PC levels > 70% carried the mutation identified in the proband. The spectrum of recurrent mutations in Spain is different from that found in the Netherlands, where the most frequent mutations were p.Gln174* and p.Arg272Cys, and is more similar to that found in France, where the most frequent were p.Arg220Gln and p.Pro210Leu. In our study, p.Val339Met (9 families), p.Tyr166Cys (7), p.Arg220Gln (6), and p.Glu58Lys (5) were the most prevalent. This study confirms the considerable heterogeneity of the genetic abnormality in PC deficiencies, and allowed genetic counseling to those individuals whose PC levels were close to the lower limit of the normal reference range.


Assuntos
Mutação/genética , Deficiência de Proteína C/genética , Proteína C/genética , Tromboembolia Venosa/genética , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Coagulação Sanguínea/genética , Criança , Pré-Escolar , Análise Mutacional de DNA , França , Humanos , Anamnese , Pessoa de Meia-Idade , Países Baixos , Linhagem , Espanha , Adulto Jovem
20.
Anal Chim Acta ; 1028: 59-65, 2018 Oct 22.
Artigo em Inglês | MEDLINE | ID: mdl-29884354

RESUMO

The development of high-throughput immunochemical assays to assist on precision medicine for patients treated with coumarin oral anticoagulants (OA) is reported. The assays are able to quantitate Warfarin (W) and/or Acenocoumarol (ACL) directly in plasma samples without any previous sample pretreatment. The detectabilities (W, 3.52 ±â€¯2.25 nM and ACL, 1.56 ±â€¯0.64 nM) and the working ranges achieved (W, 1.19 ±â€¯0.73 to 12.05 ±â€¯2.99 nM and ACL 0.63 ±â€¯0.20 to 10.19 ±â€¯6.69 nM) are within the therapeutic levels usually found in patients treated with these drugs. The assays are specific with only cross-recognition of 4'-NH2-ACL on the ACL ELISA, which is one of the main metabolites of this drug. Moreover, accuracy studies performed with blind spiked samples show very good correlation between the spiked and the measured concentrations. Finally, a small clinical pilot study has been performed analyzing 96 plasma samples from treated and untreated patients, showing that the assay is able to quantitate ACL. The results obtained allow envisaging the possibility to use these assays for pharmacokinetic studies, dosage assessment or therapeutic drug monitoring.


Assuntos
Anticoagulantes/sangue , Análise Química do Sangue/métodos , Cumarínicos/sangue , Monitoramento de Medicamentos/métodos , Ensaio de Imunoadsorção Enzimática/métodos , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA